

International Parkinson and Movement Disorder Society Pan American Section

1st Pan American Parkinson's Disease and Movement Disorders Congress FEBRUARY 24-26, 2017 MIAMI, FLORIDA, USA

FINAL PROGRAM

www.pascongress2017.org





Table of Contents

About MDS	2
About MDS-PAS	4
CME Information	5
InterContinental Miami Floor Plan	
PAS Congress Schedule-At-A-Glance	7
Friday, February 24, 2017	8
Saturday, February 25, 2017	10
Sunday, February 26, 2017	12
Faculty	14
Poster Session Schedule	16
Guided Poster Tours	
Abstracts by Topic	18
Corporate Therapeutic Symposia	27
Acknowledgements	
Certificate of Attendance	

Dear Colleagues,

On behalf of the International Parkinson and Movement Disorder Society – Pan American Section (MDS-PAS), we would like to formally welcome you to Miami, FL, USA for the 1st Pan American Parkinson's Disease and Movement Disorders Congress.

We are excited to have you participate in this important meeting, which gives us a forum to discuss relevant issues in our field that are specific to the Pan American Section. This will also be a tremendous opportunity for you to interact with colleagues from different parts of Pan America.

We hope that along with networking with colleagues, you are able to take full advantage of the exceptional Scientific Program, visit the exhibit and poster hall, participate in guided poster tours and witness the first Challenging Case MDS-PAS Rounds.

We welcome you to Miami and thank you for taking the opportunity to be part of this inaugural event.

Warmest regards,



Cyrthie Cemelle

Cynthia Comella Chair, PAS Congress Scientific Program Committee



francisco Cardodo

Francisco Cardoso

Chair, MDS-PAS







The International Parkinson and Movement Disorder Society (MDS) is a professional society of clinicians, scientists, and other healthcare professionals who are interested in Parkinson's disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control.

Purpose, Mission and Goals

Purpose:

The objective and mission of the Society shall be to advance the neurological sciences pertaining to Movement Disorders; to improve the diagnosis and treatment of patients; to operate exclusively for scientific, scholarly and educational purposes; to encourage research; to provide forums, such as medical journals, scientific symposia and International Congresses, for sharing ideas and for advancing the related clinical and scientific disciplines; to encourage interest and participation in the activities of the Society among healthcare and allied professionals and scientists; and to collaborate with other related professional and lay organizations.

Mission and Goals:

To disseminate knowledge about Movement Disorders by:

- Providing educational programs for clinicians, scientists and the general public designed to advance scientific and clinical knowledge about Movement Disorders
- Sponsoring International Congresses and Symposia on Movement Disorders
- Collaborating with other international organizations and lay groups
- Publishing journals, videotapes and other collateral materials committed to high scientific standards and peer review

To promote research into causes, prevention and treatment of Movement Disorders by:

- Using the Society's influence and resources to enhance support for research
- Facilitating the dissemination of information about research
- Encouraging the training of basic and clinical scientists in Movement Disorders and related disorders

For the purposes of favorably affecting the care of patients with Movement Disorders, the Society will provide expertise, advice and guidance to:

- Regulatory agencies to assist them in the approval process of safe and effective therapeutic interventions
- The public (media) and patient support groups by informing them of new research and therapeutic advances
- Governments to assist them in the development of policies that affect support of research and patient care
- Educational efforts to assist in developing standards of training in the specialty

MDS Officers (2015-2017)



President Oscar Gershanik, Argentina



President-Elect Christopher Goetz, USA



Secretary Claudia Trenkwalder, Germany



Secretary-Elect Susan Fox, Canada



Treasurer David John Burn, *United Kingdom*



Treasurer-Elect

Victor Fung,

Australia

Past-President Matthew Stern, USA

21st International Congress of Parkinson's Disease and Movement Disorders

SAVE THE DATE June 4–8, 2017 VANCOUVER British Columbia, Canada

www.mdscongress2017.org

Important Dates: Abstract Submission Closes January 6, 2017 Early Registration Deadline April 3, 2017 Final Pre-Registration Deadline May 2, 2017

MAN



International Parkinson and Movement Disorder Society



About MDS-PAS

Mission and Goals:

The mission of the MDS-PAS is to represent and promote the International Parkinson and Movement Disorder Society (MDS) in Pan America. Membership is open to all members of MDS within the Pan American region.

MDS-PAS aims to facilitate communication between clinicians and researchers in the region; disseminate updated knowledge about Movement Disorders; improve quality of life and independence of Movement Disorders patients and caregivers; and promote research in Movement Disorders within the region.

MDS-PAS Officers (2015-2017)





Chair Francisco Cardoso, Brazil

Chair-Elect Henrique Ferraz, Brazil



Secretary Emilia Gatto, Argentina



Charles Adler, USA Francisco Cardoso, Brazil Cynthia Comella, USA Jorge Juncos, USA Carlos Singer, USA Matthew Stern, USA



Secretary-Elect Hubert Fernandez, USA



Treasurer Janis Miyasaki, Canada





Pedro Chana-Cuevas, Chile

Past Chair Jorge Juncos, USA

PAS Congress Scientific Program Committee

Chair: Cynthia Comella, USA Francisco Cardoso, Brazil Pedro Chana-Cuevas, Chile Robert Chen, Canada Emilia Gatto, Argentina Oscar Gershanik, Argentina Christopher Goetz, USA Jennifer Goldman, USA Marcelo Merello, Argentina Jill Ostrem, USA Mayela Rodriguez Violante, Mexico Carlos Singer, USA David Standaert, USA

CME Information

Purpose

The purpose of the 1st Pan American Parkinson's Disease and Movement Disorders Congress is to offer a forum for clinical and basic science discussion on a variety of movement disorder topics, including presentations of current research and available treatments.

Learning Objectives

Through state-of-the-art lectures, hot topic reviews, controversy debates, teaching courses, skills workshops and video sessions, participants will be better able to:

- 1. Describe the pathophysiology and neurobiology of Parkinson's disease and other movement disorders;
- 2. Discuss the diagnostic approaches and tools available for Parkinson's disease and other movement disorders;
- 3. Discuss the pharmacological and non-pharmacological treatment options available for Parkinson's disease and other movement disorders.

Accreditation Statement

The International Parkinson and Movement Disorder Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The International Parkinson and Movement Disorder Society designates this live activity for a maximum of 20 *AMA PRA Category 1 Credits*[™]. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Target Audience

As the PAS Congress content is expansive and will focus on the Americas, the intended audience will comprise practitioners in the Pan American region whose clinical practice addresses the medical needs of patients with movement disorders. Some attendees are also currently involved in clinical research.

Financial Disclosure Information

It is the policy of the International Parkinson and Movement Disorder Society (MDS) to ensure balance, independence, objectivity and scientific rigor in all sponsored educational activities. All persons in control of content, including: planners, faculty and reviewers, participating in any MDS sponsored activities are required to disclose to the activity audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the Continuing Medical Education (CME) activity. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations who have products or services regardless of presentation topic. The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation. It is merely intended that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It remains for the audience to determine whether the speaker's outside interest may reflect a possible bias in either the exposition or the conclusions presented.

All financial disclosure information will be provided to participants in Miami at the MDS membership booth and on the PAS Congress website:

www.pascongress2017.org/MDS-PAS-2017/Program.htm

Claiming CME Credit

To claim CME credit for participation in the 1st Pan American Parkinson's Disease and Movement Disorders Congress participants must complete and submit an online CME Claim Form.

Instructions for claiming credit: After February 25, 2017, please visit www.pascongress2017.org/cme.

- 1. Log in after reading the instructions on the page. You will need your Member ID, which is located on your name badge. If you do not have your Member ID, please e-mail info@movementdisorders.org.
- 2. Follow the on-screen instructions to claim CME credit for the sessions you attended.
- 3. You may print your certificate from your home or office, or save it as a PDF for your records.

If you have any questions or need help claiming credit, please contact the MDS International Secretariat at education@movementdisorders.org


Evaluations


All CME Sessions:

All sessions for CME credit will have hard copies of the evaluation distributed in the course. These must be completed and handed to the course liaison as you leave the course.



InterContinental Miami Floor Plan





PAS Congress Schedule-At-A-Glance

	Friday, February 24	Saturday, February 25	Sunday, February 26		
8:00 8:30 9:00		Plenary Session 8:00 - 10:00	Plenary Session 8:00 - 9:30		
9:30			Break 9:30 - 10:00		
10:00	Plenary Session 9:30 - 11:00	Break 10:00 - 10:30	5.50 10.00		
10:30			Plenary Session		
11:00	Break 11:00 - 11:30	Plenary Session 10:30 - 12:00	10:00 - 12:00		
11:30					
12:00		Break 12:00 - 12:15	Break 12:00 - 12:15		
12:30	Plenary Session 11:30 - 13:30	Corporate Therapeutic Symposia 12:15 - 13:15	Corporate Therapeutic Symposia 12:15 - 13:15		
13:00					
13:30	Break	Break & Poster Session/ Guided Poster Tours	Break & Poster Session/ Guided Poster Tours		
14:00	13:30 - 14:30	13:00 - 14:30	13:00 - 14:30		
14:30					
15:00	Plenary Session	Parallel Sessions	Parallel Sessions		
15:30	14:30 - 16:30	14:30 - 16:30	14:30 - 16:30		
16:00					
16:30	Break 16:30 - 17:00	Break 16:30 - 17:00			
17:00					
17:30	Parallel Sessions	Skills Workshops 17:00 - 18:30			
18:00	17:00 - 19:00				
18:30		Break	— 1% —		
19:00	Break 19:00 - 19:30	18:30 - 19:30			
19:30					
20:00	Opening Ceremony 19:30 - 21:00				
20:30	19.50 21.00	Challenging Case MDS-PAS Rounds 19:30 - 22:00	Scan to learn more		
21:00		19.30 22.00	on our website		
21:30					
22:00					



Friday, February 24, 2017

1101	Themed Plenary Session 💮
	Parkinson's Disease Across
	the Americas
	9:30 – 11:00
Location:	Versailles Ballroom
Chairs:	Oscar Gershanik Buenos Aires, Argentina
	Stanley Fahn
	New York, NY, USA
9:30	How Levodopa Therapy for Parkinson's Disease Came to be Developed in the Americas
	Stanley Fahn <i>New York, NY, USA</i>
10:00	Parkinson's Disease Genetics Across the Americas
	Jeffery Vance <i>Miami, FL, USA</i>
10:30	Therapeutics: Accessibility, Cultural Differences and Habits Across the Americas
	Oscar Gershanik
	Buenos Aires, Argentina
	led Audience: Basic Scientists, Clinical Academicians, an Health Professionals, Practitioners, Students/ 'ainees
At the cond better able	clusion of this session, participants should be
1. Describ Parkins	e the emergence of levodopa as a treatment for on's disease: the American experience

- 2. Discuss the polymorphisms and risk alleles of the different populations in the Americas
- 3. Recognize how cultural differences, ingrained habits and access to different treatment options determine therapeutic decisions across the Americas

Plenary Session 1102

From Bench to Bedside -**Clinico-Pathological Markers** of Parkinson's Disease 11:30 - 13:30

Location: Chairs:	Versailles Ballroom Sarah Camargos <i>São Paulo, Brazil</i>
	Jennifer Goldman <i>Chicago, IL, USA</i>
11:30	Evidence for a Systemic Synucleinopathy C. Warren Olanow <i>New York, NY, USA</i>
12:10	The Potential Role of Tissue and Fluid Biomarkers Kathleen Shannon <i>Madison, WI, USA</i>

1102	Plenary Session, cont.
12:50	The Spread of Synuclein in
	Parkinson's Disease
	Jeffrey Kordower
Decommond	Chicago, IL, USA
	led Audience: Basic Scientists, Clinical Academicia an Health Professionals, Practitioners, Students/ ainees
At the cond better able	lusion of this session, participants should be
	the latest scientific findings regarding the
presenc	e of synuclein in the central and peripheral
	s system in Parkinson's disease
	recent data on the potential role of a tissue a
	omarkers theories and evidence regarding the spread
	in in the pathogenesis of Parkinson's disease
1103	Plenary Session
	Update on Parkinson's
	Disease Therapeutics
	•
Location:	Disease Therapeutics
	Disease Therapeutics 14:30 – 16:30 Versailles Ballroom Cecilia Peralta
	Disease Therapeutics 14:30 – 16:30 Versailles Ballroom Cecilia Peralta Buenos Aires, Argentina
	Disease Therapeutics 14:30 – 16:30 Versailles Ballroom Cecilia Peralta <i>Buenos Aires, Argentina</i> David Standaert
Location: Chairs:	Disease Therapeutics 14:30 – 16:30 Versailles Ballroom Cecilia Peralta Buenos Aires, Argentina David Standaert Bermingham, AL, USA
Chairs:	Disease Therapeutics 14:30 – 16:30 Versailles Ballroom Cecilia Peralta Buenos Aires, Argentina David Standaert Bermingham, AL, USA Levodopa: Old Drug, New
Chairs:	Disease Therapeutics 14:30 – 16:30 Versailles Ballroom Cecilia Peralta Buenos Aires, Argentina David Standaert Bermingham, AL, USA Levodopa: Old Drug, New Approaches
Chairs:	Disease Therapeutics 14:30 – 16:30 Versailles Ballroom Cecilia Peralta Buenos Aires, Argentina David Standaert Bermingham, AL, USA Levodopa: Old Drug, New Approaches Robert Hauser
Chairs: 14:30	Disease Therapeutics 14:30 – 16:30 Versailles Ballroom Cecilia Peralta Buenos Aires, Argentina David Standaert Bermingham, AL, USA Levodopa: Old Drug, New Approaches Robert Hauser Tampa, FL, USA
Chairs:	Disease Therapeutics 14:30 – 16:30 Versailles Ballroom Cecilia Peralta Buenos Aires, Argentina David Standaert Bermingham, AL, USA Levodopa: Old Drug, New Approaches Robert Hauser
Chairs: 14:30	Disease Therapeutics 14:30 – 16:30 Versailles Ballroom Cecilia Peralta Buenos Aires, Argentina David Standaert Bermingham, AL, USA Levodopa: Old Drug, New Approaches Robert Hauser Tampa, FL, USA Next Generation Deep Brain
Chairs: 14:30	Disease Therapeutics 14:30 – 16:30 Versailles Ballroom Cecilia Peralta Buenos Aires, Argentina David Standaert Bermingham, AL, USA Levodopa: Old Drug, New Approaches Robert Hauser Tampa, FL, USA Next Generation Deep Brain Stimulation
Chairs: 14:30 15:10	Disease Therapeutics 14:30 – 16:30 Versailles Ballroom Cecilia Peralta Buenos Aires, Argentina David Standaert Bermingham, AL, USA Levodopa: Old Drug, New Approaches Robert Hauser Tampa, FL, USA Next Generation Deep Brain Stimulation Jill Ostrem San Francisca, CA, USA Non-Motor Therapies: Present
Chairs: 14:30	Disease Therapeutics 14:30 – 16:30 Versailles Ballroom Cecilia Peralta Buenos Aires, Argentina David Standaert Bermingham, AL, USA Levodopa: Old Drug, New Approaches Robert Hauser Tampa, FL, USA Next Generation Deep Brain Stimulation Jill Ostrem San Francisco, CA, USA Non-Motor Therapies: Present and Future
Chairs: 14:30 15:10	Disease Therapeutics 14:30 – 16:30 Versailles Ballroom Cecilia Peralta Buenos Aires, Argentina David Standaert Bermingham, AL, USA Levodopa: Old Drug, New Approaches Robert Hauser Tampa, FL, USA Next Generation Deep Brain Stimulation Jill Ostrem San Francisco, CA, USA Non-Motor Therapies: Present and Future Cecilia Peralta
Chairs: 14:30 15:10 15:50	Disease Therapeutics 14:30 – 16:30 Versailles Ballroom Cecilia Peralta Buenos Aires, Argentina David Standaert Bermingham, AL, USA Levodopa: Old Drug, New Approaches Robert Hauser Tampa, FL, USA Next Generation Deep Brain Stimulation Jill Ostrem San Francisco, CA, USA Non-Motor Therapies: Present and Future Cecilia Peralta Buenos Aires, Argentina
Chairs: 14:30 15:10 15:50 Recommenc Non-Physicia	Disease Therapeutics 14:30 – 16:30 Versailles Ballroom Cecilia Peralta Buenos Aires, Argentina David Standaert Bermingham, AL, USA Levodopa: Old Drug, New Approaches Robert Hauser Tampa, FL, USA Next Generation Deep Brain Stimulation Jill Ostrem San Francisco, CA, USA Non-Motor Therapies: Present and Future Cecilia Peralta Buenos Aires, Argentina Health Professionals, Practitioners, Students/
Chairs: 14:30 15:10 15:50 Recommenc Non-Physicia Residents/Tr	Disease Therapeutics 14:30 – 16:30 Versailles Ballroom Cecilia Peralta Buenos Aires, Argentina David Standaert Bermingham, AL, USA Levodopa: Old Drug, New Approaches Robert Hauser Tampa, FL, USA Next Generation Deep Brain Stimulation Jill Ostrem San Francisco, CA, USA Non-Motor Therapies: Present and Future Cecilia Peralta Buenos Aires, Argentina Health Professionals, Practitioners, Students/

- 1. Recognize how new delivery strategies are expanding the application of levodopa
- 2. Describe how newer techniques and technologies may impact use of DBS
- 3. Recognize current and emerging therapies for nonmotor symptoms of Parkinson's disease

1204 **Parallel Session**

Dopaminergic and Cholinergic Imaging in Parkinson's Disease 17:00 - 19:00

Location: Chairs:	Versailles Ballroom A. Jon Stoessl <i>Vancouver, BC, Canada</i> Antonio Strafella
	Toronto, ON, Canada
17:00	Presynaptic Dopaminergic Imaging and its Role in Parkinson's Disease
	A. Jon Stoessl <i>Vancouver, BC, Canada</i>
17:40	Imaging in Behavioral and Cognitive Complications in Parkinson's Disease
	Antonio Strafella <i>Toronto, ON, Canada</i>
18:20	Insights From Cholinergic Imaging in Parkinson's Disease Nicolaas Bohnen Saline, MI, USA

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/ **Residents/Trainees**

At the conclusion of this session, participants should be better able to:

- 1. Discuss the clinical and research utility of different presynaptic dopaminergic PET tracers in Parkinson's disease
- 2. Recognize how dopaminergic imaging contributes to the understanding of cognitive and behavioral complications of Parkinson's disease
- 3. Describe the insights provided by cholinergic imaging on the pathophysiology of non-dopaminergic features of Parkinson's disease

Special Meeting Theme:

The PAS Congress Scientific Program Committee has selected a theme that is highlighted throughout the meeting. This year's theme, Movement Disorders in the Americas: State of the Art, will be showcased in two Plenary Sessions and two Parallel Sessions, focusing on cutting edge research into disorders relevant to the Americas. Themed sessions are designated in the program with \bigotimes .

Friday, February 24, 2017

1205	Parallel Session	1206	Themed Parallel Session 💮
Location:	Surgical Procedures in Movement Disorders 17:00 – 19:00 Chopin Ballroom		Drug- Or Toxin-Induced Movement Disorders in America 17:00 – 19:00
Chairs:	Corneliu Luca Miami, FL, USA Jill Ostrem San Francisco, CA, USA	Location: Chairs:	Brickell Room Pedro Chana-Cuevas Santiago, Chile Caroline Tanner
17:00	Lesions Versus Deep Brain Stimulation Corneliu Luca <i>Miami, FL, USA</i>	17:00	<i>San Francisca, CA, USA</i> Metal Exposure and Movement Disorders Marcelo Miranda
17:40	Latin America Experiences with Subthalamotomy Jose Obeso Madrid, Spain	17:40	<i>Santiago, Chile</i> Toxin-Induced Movement Disorders Caroline Tanner
18:20 Recommende	Focused Ultrasound William Elias <i>Charlottesvillle, VA, USA</i> ed Audience: Clinical Academicians, Practitioners,	18:20	<i>San Francisco, CA, USA</i> Drug-Induced Movement Disorders Pedro Chana-Cuevas
Non-Physicia	n Health Professionals, Students/Residents/Trainees usion of this session, participants should be		Santiago, Chile led Audience: Basic Scientists, Clinical Academicians,
for vario 2. Recogni perform manage 3. Recogni	to: the factors that contribute to patient candidacy us surgical treatments of Parkinson's disease ze the regional variability of surgical procedures ed for Parkinson's disease and the long-term ment of such patients ze the utility of focused ultrasound in the nt of movement disorders	At the conc better able 1. Recogn in move 2. Recogn and Par 3. Describ- use of d and ide	s, Students/Residents/Trainees clusion of this session, participants should be to: ize the role of metal exposure (manganese, iron) ement disorders ize the pathogenic role of toxin (MPTP, Rotenone aquat) in movement disorders e the movement disorders associated with the Irugs, from psychotropics to non psychotropics ntify clues leading to the suspicion of drug- t movement disorders
		Welcom	ne Ceremony 19:30 – 21:00

Location: Versailles Ballroom



Saturday, February 25, 2017

Julu	nddy, rebrudry za	, 20
2101	Themed Plenary Session 💮	2102
	Hyperkinetic Movement	11:30
	Disorders in Ethnic	
	Populations in the Americas 8:00 – 10:00	
Location:	Versailles Ballroom	Recommend Non-Physicia
Chairs:	Francisco Cardoso	Residents/Tr
	<i>Belo Horizonte, Brazil</i> Rachel Saunders-Pullman	At the conc
	New York, NY, USA	better able
8:00	Hyperkinetic Movement	 Identify Hunting
	Disorders in the Amish- Mennonite Population	2. Identify
	Rachel Saunders-Pullman	3. Identify
	New York, NY, USA	and cut
8:40	Genetic Dystonia in Brazil	Poster S
	Sarah Camargos <i>São Paulo, Brazil</i>	
9:20	Huntington's Disease-Like 2 and	Location:
	Other Huntington's Disease-Like	
	Diseases in the Americas Ruth Walker	Guided
	Bronx, NY, USA	
	ed Audience: Basic Scientists, Clinical Academicians,	Location:
Non-Physicia Residents/Tra	IN Health Professionals, Practitioners, Students/ ainees	
At the conc	lusion of this session, participants should be	
better able		Location:
	e the hyperkinetic movement disorders found in she was she was sh-Mennonite population	2203
	ze the heterogeneity of genetic dystonias in	
Brazil		
	the epidemiology, genetics, and clinical features ke diseases in the Americas	Location:
		Chairs:
2102	Plenary Session	
	Huntington's Disease Update 10:30 – 12:00	
Location:	Versailles Ballroom	16:30
Chairs:	Emilia Gatto	
	Buenos Aires, Argentina	
	Blair Leavitt Vancouver, BC, Canada	15:10
10:30	History of Huntington's Disease in	
	the Americas	
	Roberto Weiser <i>Caracas, Venezuela</i>	15:50
11:00	Phenotype-Genotype	13.30
	Emilia Gatto	
	Buenos Aires, Argentina	Recommend

, 20	17
2102 11:30	Plenary Session, cont. Experimental Therapies in
	Huntington's Disease Blair Leavitt <i>Vancouver, BC, Canada</i>
	led Audience: Basic Scientists, Clinical Academicians, an Health Professionals, Practitioners, Students/ ainees
better able	lusion of this session, participants should be to: the historical significance of the region in
Hunting 2. Identify 3. Identify	ton's disease development different phenotypes of Huntington's disease new therapeutics tools for Huntington's disease ting edge new therapies
Poster S	Session
	13:00 – 14:30
Location:	Abstract Numbers: 1-74 Biscayne Ballroom
Guided	Poster Tours
	Guided Poster Tour 1 13:30 – 14:30
Location:	Biscayne Ballroom Guided Poster Tour2 13:30 – 14:30
Location:	Biscayne Ballroom
2203	Parallel Session
Location:	Genetics of Parkinson's Disease 14:30 – 16:30 Versailles Ballroom
Chairs:	Karen Marder <i>Bronx, NY, USA</i> Andrew Singleton <i>Bethesda, MD, USA</i>
16:30	Genetics of Sporadic Parkinson's Disease
	Andrew Singleton Bethesda, MD, USA
15:10	Spectrum of LRRK2-and GBA- Associated Parkinson's Disease
	Karen Marder <i>New York, NY, USA</i>
15:50	Genetics of Cognitive Impairment in Parkinson's Disease
	Ignacio Fernandez Mata <i>Seattle, WA, USA</i>
Recommend	led Audience: Basic Scientists, Clinical Academicians,

Practitioners, Students/Residents/Trainees

2203 Parallel Session , cont.

At the conclusion of this session, participants should be better able to:

- 1. Recognize the genetic contributions to the cause of Parkinson's disease
- Describe the spectrum of different clinical characteristics seen in LRRK2 and GBA-associated Parkinson's disease
- Discuss the contribution of genetic factors to the development of cognitive impairment in Parkinson's disease

2204 Parallel Session

Spinocerebellar Ataxias 14:30 – 16:30

Location: Chairs:	Chopin Ballroom Stefan Pulst <i>Los Angeles, CA, USA</i>
	Mayela Rodriguez Violante <i>Mexico City, Mexico</i>
14:30	Molecular Pathogenesis
	Stefan Pulst
	Los Angeles, CA, USA
15:10	Clinical Features and Work-Up
	Anelyssa D'Abreu
	Campinas, Brazil
15:50	Current Treatments and Future Directions
	Theresa Zesiewicz <i>Oldsmar, FL, USA</i>

Recommended Audience: Clinical Academicians, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

- Describe the role of polyglutamine expansion and other molecular issues on the pathophysiology of spinocerebellar ataxias
- Recognize the main clinical features of the most prevalent spinocerebellar ataxias and improve the diagnostic approach
- Provide management to subjects with spinocerebellar ataxia, including genetic counseling, rehabilitation, as well as current and future pharmacologic interventions

Saturday, February 25, 2017

2205	Parallel Session	2306	Skills Workshop	2308	Skills Workshop		
	Parkinson's Disease Across the PAS: Cross- Cultural Influences on its Neuropsychiatric Issues 14:30 – 16:30		Challenges to Publish Movement Disorders Research for Non-English Speakers 17:00 – 18:30	Location: Chairs:	Chemodenervation in Movement Disorders 17:00 – 18:30 Brickell Room Robert Chen		
Location: Chairs:	Brickell Room Oscar Bernal-Pacheco <i>Chía, Colombia</i>	Location:	Versailles Ballroom Christopher Goetz <i>Chicago, IL, USA</i>	47.00	Toronto, ON, Canada Joseph Jankovic Houston, TX, USA		
	Bonnie Levin <i>Miami, FL, USA</i>		Marcelo Merello Buenos Aires, Argentina	17:00	Clinical and Pharmacological Aspects of Botulinum Toxins		
14:30 Neuropsychiatric Features of Parkinson's Disease: Similarities and Differences Across the		Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/ Residents/Trainees		17:30	Joseph Jankovic Houston, TX, USA Applications in Dystonia		
	Americas Oscar Bernal-Pacheco <i>Chía, Colombia</i>		ion, participants will hear the editors explain		Cynthia Comella <i>Chicago, IL, USA</i>		
15:10	Cultural Influences on Perceptions and Treatments of Neuropsychiatric Features in Parkinson's Disease	the various ways of publishing research and discuss the most common style mistakes made by non-English speakers when writing a paper. The presenters will address how writing a scientific paper is a difficult and highly skilled process, which starts with posing a hypothesis		18:00 Applications in Parkinsonism Robert Chen <i>Toronto, ON, Canada</i> Recommended Audience: Clinical Academicians, Practitioner Non-Physician Health Professionals, Students/Residents/Trai			
15:50	Jennifer Goldman <i>Chicago, IL, USA</i> Neuropsychological Evaluations	and develops into the proper methodology. Participants will see how transmitting and convincing the medical community about the validity and relevance of research			Session Description: In this session, participants with be given an overview of the applications of Botulinum toxin. One of the pioneers		
	in Parkinson's Disease in the Context of Culture and Language Bonnie Levin <i>Miami, FL, USA</i>	better able	lusion of this session, participants should be to:	in the use participan	of Botulinum toxin, Dr. Jankovic, will introduce ts to recent biotechnological developments I. Dr. Comella will also share her views on the		
Practitioner: Residents/Ti	led Audience: Basic Scientists, Clinical Academicians, s, Non-Physician Health Professionals, Students/ rainees	writing 2. Identify 3. Discuss	ize that publication of research starts before a paper different ways of publishing their research the most common style mistakes made by non-	Dr. Chen w different to	use of electromyography and other techniques. ill provide an overview of proper targeting, echniques, expected benefits and side effect his versatile therapy.		
better able		English speakers when writing a paper 2307 Skills Workshop		At the conclusion of this session, participants should be better able to:			
of neur behavio	 Describe the epidemiology and clinical features of neuropsychiatric problems affecting cognition, behavior, and mood in Parkinson's disease across the 		MDS-UPDRS and UDysRS 17:00 – 18:30	pharma	the mechanisms of action and clinical acological effects of the different formulations of um toxins		
 Pan Americas Discuss how cultural differences influence our perceptions, recognition, and management of neuropsychiatric features in Parkinson's disease Discuss the effects of cultural and language on 		Location: Chopin Ballroom Mayela Rodriguez Violante <i>Mexico City, Mexico</i> Glenn Stebbins <i>Chicago, IL, USA</i>		 Describe the use of Botulinum toxin for the focal dystonias Describe the use of Botulinum toxin in the treatmen the motor and non-motor manifestations of Parkin disease 			
in the e	neuropsychological testing, normative data, particularly in the evaluation of neuropsychiatric features of				Challenging Case MDS-PAS Rounds		
Parkinson's disease		s disease Session Description: In this session, participants will be provided with the tools to understand the MDS-UPDRS and UDsyRS, its administration and scoring so that they can be used in		Location: Experts:	19:30 – 22:00 Versailles Ballroom Alberto Espay <i>Cincinnati, OH, USA</i>		

administration and scoring so that they can be used in clinical practice and research. At the conclusion of this session, participants should be better able to:

- 1. Describe the conceptual constructs of the MDS-UPDRS and UDysRS
- 2. Engage patients and caregivers in their role in the MDS-UPDRS and UDysRS
- 3. Complete sample ratings on items in the MDS-UPDRS and UDysRS

Witness clinical experts present and discuss a case by phenomenology, syndromic classification and differential diagnosis.

Steven Frucht

Helio Teive *Curitiba, Brazil*

New York, NY, USA



Sunday, February 26, 2017

3101	Plenary Session	3102	Plenary Session, cont.	3203	Themed Parallel Session 💮
	Hot Topics in Movement Disorders 8:00 – 9:30	10:40	Is There a Role for Immunotherapy for Synucleinopathies? (YES) Elvira Valera	3203	Inflammation, Infections and Immunity in Movement Disorders
Location: Chairs:	Versailles Ballroom Jorge Juncos		La Jolla, CA, USA		14:30 – 16:30
Cildiis.	Atlanta, GA, USA Irene Litvan La Jolla, CA, USA	11:00	Is There a Role for Immunotherapy for Synucleinopathies? (NO) David Standaert	Location: Chairs:	Versailles Ballroom Mayela Rodriguez Violante <i>Mexico City, Mexico</i>
8:00	Deep Brain Stimulation for Tourette's Syndrome	11.00	Birmingham, AL, USA		Helio Teive <i>Curitiba, Brazil</i>
	Michael Okun Gainesville, FL, USA	11:20	Is Genetics In, and Clinical Phenomenology Out? (YES)	14:30	Inflammation and Movement Disorders
8:30	Emerging Treatments for Tauopathies		Laurie Ozelius <i>Charlestown, MA, USA</i>		David Standaert <i>Birmingham, AL, USA</i>
	Irene Litvan La Jolla, CA, USA	11:40	ls Genetics In, and Clinical Phenomenology Out? (NO)	15:10	Viral and Parasitic Infections Carlos Cosentino
9:00	Stem Cell Tourism		Connie Marras		Lima, Peru
2.00	Carlos Singer Miami, FL, USA		Toronto, ON, Canada ded Audience: Basic Scientists, Clinical Academicians,	15:50	Post Infectious and Autoimmune Movement Disorders
	Indunty, FL, OSA Jed Audience: Basic Scientists, Clinical Academicians, an Health Professionals, Practitioners, Students/	Non-Physici Residents/Ti	an Health Professionals, Practitioners, Students/ rainees		Francisco Cardoso <i>Belo Horizonte, Brazil</i>
Residents/Ti			clusion of this session, participants should be		ded Audience: Clinical Academicians, Practitioners,
At the cond	clusion of this session, participants should be	better able	to: tand the difficulties of an early diagnosis in		esidents/Trainees
better able			on's disease	At the con better able	clusion of this session, participants should be
	current options for surgical intervention in e's syndrome		the promises and pitfalls of immunotherapy in		nize the role of inflammation in the
	ize recent advances in the treatment of	3. Discuss	on's disease the value of clinical phenomenology vs. whole sequencing	2. Identif	physiology of movement disorders y the pathogenesis features of viral infection and
	the risks of uncontrolled advertising				ic causing movement disorders
	bstantiated stem cell treatments for egenerative diseases	Poster	Session		nize the pathogenesis or post infectious and Imune movement disorders
	-		13:00 – 14:30 Abstract Numbers: 75-150		
3102	Plenary Session	Location:	Biscayne Ballroom		
	Controversies 10:00 – 12:00	Guided	Poster Tours		
Location: Chairs:	Versailles Ballroom Cynthia Comella		Guided Poster Tour 3 13:00 – 14:30		
	Chicago, IL, USA Marcelo Merello Buenos Aires, Argentina	Location:	Biscayne Ballroom Guided Poster Tour 4 13:00 – 14:30		
10:00	Can We Diagnose Parkinson's Disease at an Early or Prodromal Stage? (YES) Matthew Stern Philadelphia, PA, USA	Location:	Biscayne Ballroom		
10:20	Can We Diagnose Parkinson's Disease at an Early or Prodromal Stage? (NO) Ron Postuma				
	Montreal, QC, Canada				

Sunday, February 26, 2017

3204	Parallel Session	3205	Parallel Session	
	Focus on the Patient/Family: Completing the Circle of Care in the Americas		Rare Movement Disorders: What We Can Learn? 14:30 – 16:30	
	14:30 – 16:30	Location:	Brickell Room	
Location: Chairs	Chopin Ballroom Pedro Chana-Cuevas	Chairs:	Emilia Gatto Buenos Aires, Argentina	
	<i>Santiago, Chile</i> Ruth Hagestuen		Anthony Lang <i>Toronto, ON, Canada</i>	
14:30	Minnetonka, MN, USA Focus on the Patient/Family:	14:30	Approach to Rare Movement Disorders	
14.50	Completing the Circle of Care Elaine Book		Anthony Lang <i>Toronto, ON, Canada</i>	
15:10	Vancouver, BC, Canada Home Management, Family and	15:10	Neurodegeneration with Brain Iron Accumulation	
15:10	People with Parkinson's Disease		Susan Hayflick Portland, OR, USA	
	Daniela Alburquerque Santiago, Chile	15:50	Gaucher Disease and Niemann	
15:50	Palliative Care and Parkinson's Disease		Pick Type C Emilia Gatto Buenos Aires, Argentina	
	Julie Carter <i>Portland, OR, USA</i>	Recommended Audience: Basic Scientists, Clinical Academicia		
	led Audience: Clinical Academicians, Practitioners, an Health Professionals, Students/Residents/Trainees		s, Non-Physician Health Professionals, Students/	
 At the conclusion of this session, participants should be better able to: 1. Identify the impact of Parkinson's disease on the care partners in the early, middle and advanced stages of Parkinson's disease as well as options for support along the journey 2. Distinguish different alternatives in Parkinson's disease 		At the conclusion of this session, participants should be better able to:		
		 Recognize rare movement disorders and explain how these conditions contribute to the understanding of more common disorders Explain clinical and pathologic features of degenerative disorders with brain iron accumulation 		

- 2. Distinguish different alternatives in Parkinson's disease care within the home, consider cultural and family perspective
- 3. Identify key palliative care with respect to Parkinson's disease and how a palliative care approach can be used throughout the disease trajectory
- disorders with brain iron accumulation 3. Discuss the clinical features, diagnosis and treatment of Gaucher disease and Niemann Pick Type C



Faculty

Daniela Alburquerque Santiago, Chile 3204

Oscar Bernal-Pacheco *Chía, Colombia* 2205

Nicolaas Bohnen Saline, MI, USA 1204

Elaine Book Vancouver, BC, Canada 3204

Sarah Camargos São Paulo, Brazil 1102, 2101

Francisco Cardoso *Belo Horizonte, Brazil* 2101, 3203

Julie Carter Portland, OR, USA 3204

Robert Chen *Toronto, ON, Canada* 2308

Cynthia Comella *Chicago, IL, USA* 2308, 3102

Carlos Cosentino *Lima, Peru* 3203

Pedro Chana-Cuevas Santiago, Chile 1206, 3204

Anelyssa D'Abreu Campinas, Brazil 2204

William Elias *Charlottesville, VA, USA* 1205

Alberto Espay Cincinnati, OH, USA Challenging Case MDS-PAS Rounds

Stanley Fahn *New York, NY, USA* 1101

Ignacio Fernandez Mata *Seattle, WA, USA* 2203 Steven Frucht New York, NY, USA Challenging Case MDS-PAS Rounds

Emilia Gatto *Buenos Aires, Argentina* 2102, 3205

Oscar Gershanik Buenos Aires, Argentina 1101

Christopher Goetz *Chicago, IL, USA* 2306

Jennifer Goldman *Chicago, IL, USA* 1102, 2205

Ruth Hagestuen *Minnetonka, MN, USA* 3204

Robert Hauser *Tampa, FL, USA* 1103

Susan Hayflick Portland, OR, USA 3205

Joseph Jankovic Houston, TX, USA

2308 Jorge Juncos Atlanta, GA, USA 3101

Jeffrey Kordower Chicago, IL, USA 1102

Anthony Lang *Toronto, ON, Canada* 3205

Blair Leavitt *Vancouver, BC, Canada* 2102

Bonnie Levin *Miami, FL, USA* 2205

Irene Litvan *La Jolla, CA, USA* 3101

Corneliu Luca *Miami, FL, USA* 1205 Karen Marder New York, NY, USA 2203

Connie Marras *Toronto, ON, Canada* 3102

Marcelo Merello Buenos Aires, Argentina 2306

Marcelo Miranda Santiago, Chile 1206

Jose Obeso Madrid, Spain 1205

Michael Okun Gainesville, FL, USA 3101

C. Warren Olanow *New York, NY, USA* 1102

Jill Ostrem San Francisco, CA, USA 1103, 1205

Laurie Ozelius Charlestown, MA, USA 3102

Cecilia Peralta Buenos Aires, Argentina 1103

Ron Postuma *Montreal, QC, Canada* 3102

Stefan Pulst *Los Angeles, CA, USA* 2204

Mayela Rodriguez Violante Mexico City, Mexico 2204, 2307, 3203

Rachel Saunders-Pullman New York, NY, USA 2101

Kathleen Shannon Madison, WI, USA 1102

Carlos Singer *Miami, FL, USA* 3101 **Andrew Singleton** *Bethesda, MD, USA* 2203

David Standaert Birmingham, AL, USA 1103, 3102, 3203

Glenn Stebbins *Chicago, IL, USA* 2307

Matthew Stern Philadelphia, PA, USA 3102

A. Jon Stoessl Vancouver, BC, Canada 1204

Antonio Strafella *Toronto, ON, Canada* 1204

Caroline Tanner San Francisco, CA, USA 1206

Helio Teive Curitiba, Brazil 3203, Challenging Case MDS-PAS Rounds

Elvira Valera *La Jolla, CA, USA* 3102

Jeffery Vance Miami, FL, USA 1101

Ruth Walker Bronx, NY, USA 2101

Roberto Weiser *Caracas, Venezuela* 2102

Theresa Zesiewicz *Oldsmar, FL, USA* 2204




LEVEL



INTREPID Clinical Research Study Implantable Neurostimulator for the treatment of Parkinson's Disease

Scientific



Scientific

VERCISE



Poster Session Schedule

Saturday, February 25, 2017 Sunday, Feb	Sunday, February 26, 2017		
Poster Session:13:00 - 14:30Poster Session:Poster Viewing Hours:9:00 - 17:00Poster Viewing	Poster Session: 13:00 - 14:30 Poster Viewing Hours: 9:00 – 17:00 Location: Biscayne Ballroom		
1-7Ataxia75-92Par8-9Choreas (Non-Huntington's Disease)93-96Par10-13Clinical Trials and Therapy in Movement Disorders97-108Par14Cognitive Disorders109-114Par15-21Drug-Induced Movement Disorders115-121Par22-28Dystonia122-132Par29-30Education in Movement Disorders133-137Par31-36Epidemiology138-139Par38Genetics (Non-Parkinson's Disease)140-146Phe39-43Huntington's Disease147-148Sur	arkinson's Disease: Clinical Trials, Pharmacology and Treatment arkinsonism, MSA, PSP (Secondary and Parkinsonism-Plus) arkinson's Disease: Cognition arkinson's Disease: Neuroimaging and Neurophysiology arkinson's Disease: Non-Motor Symptoms arkinson's Disease: Pathophysiology arkinson's Disease: Pathophysiology arkinson's Disease: Psychiatric Manifestations henomenology and Clinical Assessment of Movement Disorders urgical Therapy: Other Movement Disorders urgical Therapy: Parkinson's Disease		

Late-Breaking Abstracts will be on display Saturday and Sunday during normal Poster Viewing Hours. They will be presented on Saturday, February 25, 2017 from 13:00 - 14:30.

Guided Poster Tours

Guided Poster Tour 1

Saturday, February 25, 2017	13:30-14:30
-----------------------------	-------------

Includes the top scoring abstracts in the following categories: Ataxia Clinical Trials and Therapy in Movement Disorders Dvstonia

Leaders: A. Jon Stoessl and Helio Teive

Guided Poster Tour 2

Saturday, February 25, 2017 13:30-14:30

Includes the top scoring abstracts in the following categories: Epidemiology Neuroimaging (Non-PD) Neurophysiology (Non-PD) **Rating Scales**

Leaders: Caroline Tanner and Mayela Rodriguez Violante

Guided Poster Tour 3

Sunday, February 26, 2017

13:00-14:30

Includes the top scoring abstracts in the following categories: Parkinson's Disease: Clinical Trials, Pharmacology and Treatment Parkinson's Disease: Cognition

Leaders: Susan Fox and Marcelo Merello

Guided Poster Tour 4

Sunday, February 26, 2017 13:00-14:30

Includes the top scoring abstracts in the following categories: Parkinson's Disease: Genetics Parkinson's Disease: Neuroimaging and Neurophysiology Parkinsonism, MSA, PSP (Secondary and Parkinsonism-Plus) Parkinson's Disease: Non-Motor Symptoms

Leaders: Jennifer Goldman and Emilia Gatto



ww.acorda.com

Acorda Therapeutics is proud to be a Gold Level Sponsor at the 1st Pan American Parkinson's Disease and Movement Disorders Congress. We're proud to support their objectives to improve the quality of life and independence of people with Parkinson's.



Ataxia

- Early interventions in sca2: Ethical considerations and neurorehabilitation therapy Luis Velázquez-Pérez, Julio Cesar Rodriguez Diaz, Roberto Rodríguez-Labrada, Jacqueline Medrano-Montero, Annelié Estupiñan-Rodriguez, Lorenzo Reynaldo Cejas, Mariela Gongora Marrero, Miguel Velazquez-Santos, Yanetza Gonzalez Zaldivar, Reydenis Torres-Vega (Holguín, Cuba)
- 2 Biomarkers of dys-executive decline in Spinocerebellar Ataxia type 2: Insights into physiopathology and therapies Roberto Rodríguez-Labrada, Luis Velázquez-Pérez, Annelié Estupiñan-Rodriguez, Reydenis Torres-Vega, Jacqueline Medrano-Montero, Ricardo Ortega-Sanchez, Yaimee Vazquez-Mojena, Arnoy Peña Acosta, Nalia Canales-Ochoa (Holguin, Cuba)
- 3 Ataxia, 83 clinical case series Paula Saffie (Santiago de Chile, Chile)
- 4 Withdrawn by author
- 5 Fragile x associated tremor / ataxia syndrome (fxtas) atypical presentation Mauricio Chamorro (Rosario, Argentina)
- 6 Comparison of mental practice and proprioceptive neuromuscular facilitation in sisters with cerebellar atrophy Cynthia Bedeschi, Diego Guedes, Daniela Ambrosano (Sao Paulo, Brazil)
- 7 Steroid-Responsive Encephalopathy with Associated Thyroiditis (SREAT) presenting with pure cerebellar ataxia Pichet Termsarasab, Yuvadee Pitakpatapee, Steven Frucht, Prachaya Srivanitchapoom (Cleveland Heights, OH, USA)

Choreas (Non-Huntington's Disease)

- Hemichorea induced by sertraline: Case report and literature review
 Victoria Aldinio, María Bres Bullrich, Emilia Gatto, Pilar Sánchez de Paz, Gustavo Andres Da Prat de Magalhaes, Galeno Rojas, Virginia Parisi, Gabriel Persi (Buenos Aires, Argentina)
- 9 Challenges in diagnosis and treatment of acute rheumatic fever in a young female with multiple stress-related complaints Kalea Colletta, Priya Malhotra, Eugene Schnitzler (Orland Hills, IL, USA)

Clinical Trials and Therapy in Movement Disorders

- 10 Efficacy and safety of a 2 ml dilution of abobotulinumtoxina compared with placebo in adult patients with cervical dystonia Mark Lew, Daniel Snyder (Los Angeles, CA, USA)
- 11 Exploratory trial results for SAGE-547 injection in essential tremor George Nomikos, Aaron Ellenbogen, Shane Raines, Ryan Arnold, Helen Colquhoun, James Doherty, Stephen Kanes (Cambridge, MA, USA)
- 12 Clinical, demographic, imaging and long-term treatment with botulinum toxin in a series of 141 patients with facial hemispasm

Nicolas Morera, Gabriela Raina, Andrea Tschopp, Cristian Calandra, Maria Cersosimo, Ricardo Maiola, Fernando Auvieux, Silvia Folgar, Carolina Ramírez Gómez, Carol Aguilar Alvarado, Gonzalo Castro, Verónica Montilla-Uzcátegui, Cynthia Garcia Fernandez, Federico Micheli (Buenos Aires, Argentina) 13 A comparison of cycle exercise, functional training and Xbox Kinect[®] in cardiorespiratory fitness of elderly with Parkinson's disease: a randomized controlled trial Daniel Ferraz, Karen Trippo, Gabriel Duarte, Ramon Kruschewsky, Jamary Oliveira Filho (Salvador, Brazil)

Cognitive Disorders

14 Psychosocial features of patients with essential tremor in Parkinson's disease in Uzbekistan Dilshod Tolibov, Gulnora Rakhmibayeva, Azamatjon Umarov (Tashkent, Uzbekistan)

Drug-Induced Movement Disorders

- 15 Substance abuse and parkinsonsism Kaushalendra Tripathi, Richa Tripathi, Edwin George (Ahmedabad, India)
- 16 Inhaled steroid induced hemichorea-hemiballism Hee Jin Kim, Hee Jin Kang (Seoul, Korea)
- 17 Rolipram, a PDE-IV inhibitor protects against experimental parkinsonism in mice Nitin Kumar, R Khanna (New Delhi, India)
- 18 Myoclonus and tremor induced by Flunarizine and Cinnarizine: A report of four cases in El Salvador Jose Ricardo Lopez-Castellanos, Jose Lopez-Contreras (Cincinnnati, OH, USA)
- 19 Isoniazid induced myoclonus a case report Daniel Pereira Contreras (Quezaltepeque, El Salvador)
- 20 Risk of Parkinson's disease in zolpidem user: A systematic review and meta-analysis Md Salman Hussain, Abul Najmi, Dasari Anil (New Delhi, India)
- 21 A case of possible delayed akathisia due to risperidone Priya Mahajan (Kalamazoo, MI, USA)

Dystonia

- 22 A multiparametric MEG study of the effect of medications on neuronal oscillations in generalized or cervical dystonia Abhimanyu Mahajan, Susan Bowyer, Andrew Zillgitt, Peter LeWitt, Patricia Kaminski, Christos Sidiropoulos (Detroit, MI, USA)
- 23 Abobotulinumtoxina injection patterns in patients with cervical dystonia from the anchor-cd registry study Cynthia Comella, Daniel Truong, Alberto Espay, Daniel Snyder, Dominic Marchese, Richard Trosch (Chicago, IL, USA)
- 24 Bilateral facial movements following Guillian-Barre syndrome
 - Zain Guduru, Julie Kurek, John Morgan, Kapil Sethi (Augusta, GA, USA)
- 25 Demographic and clinical features in a series of 171 patients with blepharospasm after long-term treatment with botulinum toxin

Carol Aguilar Alvarado, Gabriela Raina, Nicolas Morera, Lorena Tschopp, Verónica Montilla-Uzcátegui, Carolina Ramírez Gómez, Gonzalo Castro, Cynthia Garcia Fernandez, Juan Pablo Paviolo, Verónica Tkachuk, Cristian Calandra, Luis Pellene, Graciela Cersósimo, Ricardo Maiola, Fernando Auvieux, Silvia Folgar, Federico Micheli (Quetzaltenango, Guatemala)

- 26 Withdrawn by author
- 27 Quality of life improvements persist in people with dystonia over 10 years following DBS surgery Elliot Hogg, Emmanuel During, Kishore Athreya, Echo Tan, Michele Tagliati (Beverly Hills, CA, USA)
- 28 Stimulation induced parkinsonism is uncommon in people with dystonia 10 years following DBS surgery Michele Tagliati, Jonathan Eskenazi, Emmanuel During, Kishore Athreya, Elliot Hogg (Los Angeles, CA, USA)

Education in Movement Disorders

29 Parkinson's disease risk score (PDRS) for Parkinson's disease screening in aging population: Effect of yoga and meditation

Vinod Sharma (Delhi, India)

30 Implementation process of the translation and adaptation of European Physiotherapy Guideline for Parkinson's disease to Portuguese Tamine Capato, Josefa Domingos, Lorena Almeida, Bastiaan Bloem, Samyra Keus (Sao Paulo, Brazil)

Epidemiology

- 31 Prevalence, incidence and risk factors associations of Parkinson's disease in an elderly population in Cuba Jorge Jesus Llibre Guerra, Juan Llibre Guerra, Erika Guartazaca Guerrero, Ana Rodriguez Salgado, Juan Pablo Diaz Marante (La Habana, Cuba)
- 32 Outpatient care for Parkinson's disease in the US: A national perspective Gurkirpal Singh, Bharathi Lingala, Amy Guo, David Squillacote, Alexander Niyazov, Alka Mithal (Palo Alto, USA)
- 33 Mortality in patients with Parkinson's disease: Analysis of data from tertiary referral movement disorder clinic Juyeon Kim, Young Jin Kim, Kiju Kim, Ho-Sung Ryu, Sun Ju Chung (Anyang, Korea)
- 34 Emergency department visits and hospitalizations for Parkinson's disease in the US: A national perspective Gurkirpal Singh, Bharathi Lingala, Alexander Niyazov, Amy Guo, David Squillacote, Alka Mithal (Palo Alto, CA, USA)
- 35 Movement disorders in El Salvador: An eleven years-survey Jose Ricardo Lopez-Castellanos, Jose Lopez-Contreras (Cincinnnati, OH, USA)
- 36 Characteristics of the onset of Parkinson's disease in a Bolivian population Juan Carlos Duran (La Paz, Bolivia)

Genetics (Non-Parkinson's Disease)

- 37 Withdrawn by author
- 38 Phenotypical variability in an Argentinian family, with history of frontotemporal lobar degeneration, caused by a mutation in the microtubule-associated protein tau Ignacio Fernandez Mata, Emilia Gatto, Ricardo Allegri, Ezequiel Surace, Gustavo Andres Da Prat de Magalhaes, Hanna David, Chrem Mendez Patricio, Dorschner Michael (Seattle, WA, USA)

Huntington's Disease

- 39 Clinical, demographic and genetic features of 73 patients with Huntington's disease in Argentina Carolina Ramírez Gómez, Natalia Araoz Olivos, Verónica Montilla-Uzcátegui, Carol Aguilar Alvarado, Gonzalo Castro, Cynthia Fernández, Ricardo Maiola, Cristian Calandra, Nicolas Morera, Andrea Tschopp, Gabriela Raina, Graciela Cersósimo, Federico Micheli (Ixtlahuaca de Cuauhtémoc, Mexico)
- 40 Clinical and demographic differences in patients with Huntington's disease according to main initial symptom Lidia Mendoza Vega, Mayela Rodriguez Violante, Amin Cervantes, Ned Davilal-Avila, Sara Isais Millan, Karla Salinas (Estado de México, Mexico)
- 41 Deficits in temporal processing correlate with clinical progression in Huntington's disease Martin Cesarini, Emilia Gatto, Jose Luis Etcheverry, Ana Sanguinetti, Patricia Agostino, Diego Golombek (La Plata, Argentina)
- 42 Magnetic resonance imaging and pyramidal impairment in Huntington's disease Emilia Gatto, Martin Cesarini, Jose Luis Etcheverry, Ana Sanguinetti, Leonardo Bevacqua, Sebastian Lescano (Buenos Aires, Argentina)
- 43 Clinical suspicion of juvenile Huntington's disease in Uruguay: Case report
 Adriana Cardozo Dodera (Maldonado, Uruguay)

Myoclonus

44 Adult-onset opsoclonus-myoclonus syndrome - small case series

Luis Tieppo Fornari, André Palmeira, Carlos Roberto Rieder, Arlete Hilbig (Porto Alegre, Brazil)

Neuroimaging (Non-Parkinson's Disease)

45 Biomarkers of abnormal motor control in handwriting: a neuroanatomical comparison Ketan Jhunjhunwala, Lija George, Rajini Naduthota, Jitender Saini, Abhishek Lenka, Lauren Giamberardino, Ravi Yadav, Pramod Pal, Priyantha Herath (Columbia, SC, USA)

Neuropharmacology

- 46 Serine Peptidase Spd2 can specifically degrade Neurotoxic Prion Protein PrPSC in vivo in Drosophila Mohammad Abu Hena Jamal, Hyeon Kim, Seong Hong (Jeonju, Korea)
- 47 Curcumin exhibit neuroprotective potential by mitigating rotenone induced oxidative and mitochondrial dysfunctions in mouse model of Parkinson's disease Dharmendra Khatri, Archana Juvekar (Mumbai, India)

Neurophysiology (Non-Parkinson's Disease)

- 48 Decreased complexity of cardiovascular autonomic regulation: A promising clinical biomarker of prodromal spinocerebellar ataxia type 2 Claudia Carricarte, Andrés Machado, Lazaro Sanchez-Rodriguez, Mario Estévez, Julio Montes-Brown, Claudia Sanchez, Dennis Francos, Luis Velázquez-Pérez (La Habana, Cuba)
- 49 The ulitity of cortical silent period to differenciate different pathologies of the pyramidal and extrapiramydal systems María Del Pilar Rodríguez Rodríguez, Carlos Armando Tello Valdes (Texcoco, Mexico)



Other

50 Withdrawn by author

- 51 Gait and anthropometric characteristics of patients with Parkinson's disease seen in a Nigerian tertiary hospital Abiola Ogundele, Matthew Olaogun, Morenikeji Komolafe (Ile-Ife, Nigeria)
- 52 Assessing barriers/motivations for participating in Parkinson's disease genetic studies in Hispanic versus Non-Hispanic whites Karen Nuytemans, Clara Manrique, Michael Cuccaro, William Scott, Corneliu Luca, Carlos Singer, Jeffery Vance (Miami, FL, USA)
- 53 Psychogenic movement disorder: Demographic and clinical profile of 52 patients Sanjay Pandey, Neelav Sarma (New Delhi, India)
- 54 Motor and body composition variables by Parkinson's disease staging Luciano Alves Leandro, Carolina Moreira (Curitiba, Brazil)
- 55 Painless legs and moving toes syndrome Laveena Singla, Sivaprasad Pesala, Syed Shah Abdullah, Pradeep Bollu (Columbia, OH, USA)
- 56 Telemedicine vs. office visits in a movement disorder specialty clinic: Comparative patient satisfaction Ryan Hanson, Christopher Goetz, Marisa Truesdal, Glenn Stebbins, Allison Weathers (Chicago, IL, USA)
- 57 Aquatic physical therapy in people with Parkinson's disease: Repercussions in functional mobility and balance Vera Israel, Thalyssa Mocelin, Juliana Siega, Adriano Silva, Bruna Yamaguchi (Curitiba, Brazil)
- 58 Aquatic physical therapy in people with Parkinson's disease: Effects on cardiorespiratory fitness Vera Israel, Juliana Siega, Thalyssa Mocelin, Bruna Yamaguchi, Adriano Silva (Curitiba, Brazil)
- 59 Effects of green tea extract (GTE) on Ca2+ ATPase and lipid peroxidation in brains of aging male rats Sumit Rajput, Sukrat Sinha (Delhi, India)

Pediatric Movement Disorder

60 A natural history of Syndenham's chorea in Filipino children: A case series

Ariel Rabanes, Marilyn Ortiz, Lillian Lee (lloilo City, Philippines)

- 61 Paroxysmal non-kinesigenic dyskinesia, complex motor tics, autism spectrum disorder, and psychiatric diseases in a family with a novel PNKD mutation Darius Ebrahimi-Fakhari, Darryl De Vivo, Timothy Yu (Boston, MA, USA)
- 62 An interesting case of potassium channelopathy mimicking paroxysmal non- kinesogenic dyskinesia Kallol Set, Debabrata Ghosh, Ahm Huq, Aimee Luat (Detroit, MI, USA)
- 63 Experience in developmental and benign movement disorders in childhood: 113 Chilean patients Valentina Naranjo Lobo, Mónica Troncoso, Andrés Barrios, Ledia Troncoso, Paola Santander, Scarlet Witting, Susana Lara, María José Hidalgo, Daniela Muñoz, Isadora Ruiz (Santiago, Chile)

64 Neurotransmitter diseases with onset age before six years old: Nine Chilean children Mónica Troncoso, Valentina Naranjo Lobo, Nelly Luza, Paola Santander, Carla Rojas, Álvaro Wicki, María Magdalena González, Isadora Ruiz, Daniela Muñoz, María José Hidalgo (Santiago, Chile)

Quality of Life/Caregiver Burden in Movement Disorders

- 65 Diagnosis and management of an extended family with Huntington's disease in a resource-limited community Emily Smith, Lindyann Lessy, Jeffon Telesford, Ruth Walker, Andrew Sobering (St. George's, Grenada)
- 66 The impact of dysarthria on quality of life in a Brazilian sample: Preliminary findings Victor Quintas, Tiago Attoni, Francisco Cardoso, Ana Teresa Britto, Hugo de Resende, Marcelo Vieira, Larissa Baracho, Rui Rothe-Neves, Serge Pinto (Belo Horizonte, Brazil)
- 67 Gait analysis and MDS-UPDRS Part II (motor experiences of daily living) in a sample of patients with Parkinson`s disease in Cali, Colombia Beatriz Munoz Ospina, Beatriz Munoz Ospina, Jorge Luis Orozco, Alejandro Enriquez (Cali, Colombia)

Rare Genetic and Metabolic Diseases

68 Clinical features of Wilson's disease in Peru: Review of eight cases

Elison Sarapura, Jorge Ramirez-Quiñones, Mario Cornejo-Olivas, Luis Torres (Lima, Peru)

Rating Scales

69 Hoehn & Yahr staging and postural stability in the MDS-UPDRS scale for Parkinson's disease Deepak Gupta, Stanley Fahn, Un Kang (New York, NY, USA)

Restless Legs Syndrome and Other Sleep Disorders

70 99mtc - trodat- 1 spect in seven patients with RLS Giorgio Fabiani, Raul Martins Filho, Helio Teive (Curitiba, Brazil)

Tremor

- 71 Patients with essential tremor (ET): Does symptoms such as mild tremor or bradykinesia detrimental to the execution of an activity of daily living? Christian Duval, Etienne Goubault, Hung Nguyen, Sarah Bogard, Genevieve Faucher, Noushin Roofigari-Esfahani (Montréal, QC, Canada)
- 72 Fragile x-associated tremor/ataxia syndrome in a female child

Shivam Mittal, Kenneth Mark, James Bower (Rochester, MN, USA)

- Differential diagnostics of essential tremor and Parkinson's disease according to electrophysiological parameters of postural tremor
 Dilshod Tolibov, Azamatjon Umarov, Gulnora Rakhmibayeva (Tashkent, Uzbekistan)
- 74 Novel treatment with levetiracetam of lower extremity myorhythmia associated with multiple sclerosis Momina Soudagar Turkey, Neha Prakash, Florian Thomas, Pratap Chand (Saint Louis, MO, USA)

Impax is committed to improving our patient support programs:



Make The **Rytary**[®]

Connection For Your Patients.

MyRytary[®] is a personalized program helping patients prescribed Rytary[®] (carbidopa and levodopa) connect to case management, access and affordability support, and educational resources. Getting started is easy. To enroll, log into MyRYTARY.com or call 1.844.IMPAX2U (467-2928).

MyRytary[®] Instant Savings Program Eligible patients pay no more than \$25 per month* 1.844.IMPAX2U Monday-Friday, 8am-8pm EST MyRYTARY.com

Come see us in Miami on February 24-26 at Booth #9.



* Subject to eligibility. For private insurance programs only. Up to \$100 maximum benefit. Individual out-of-pocket costs may vary. See terms, conditions, and eligibility criteria at https://rytary.com/patients-resources/savings-card.



© 2017 Impax Specialty Pharma, a division of Impax Laboratories, Inc., All rights reserved. Printed in USA. PP-ADP-RYT-US-0013 12/2016



Parkinson's Disease: Clinical Trials, Pharmacology and Treatment

- 75 Cognitive and cerebral changes related to an integrative cognitive rehabilitation program in Parkinson's disease Naroa Ibarretxe-Bilbao, María Díez-Cirarda, Javier Peña, Alberto Cabrera-Zubizarreta, Olaia Lucas-Jiménez, Juan Carlos Gómez-Esteban, María Ángeles Gómez-Beldarrain, Natalia Ojeda (Bilbao, Spain)
- 76 Human factors testing of the levodopa-carbidopa intestinal gel delivery system in advanced Parkinson's disease patients and healthcare providers Ramon Rodriguez, Hubert Fernandez, Alberto Espay, Rajkumar Conjeevaram, Ji Zhou, Matthew Kuntz, Edward Halpern, Janet Benesh (Orlando, FL, USA)
- 77 Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: Results from the Phase 3 study dose-titration phase Robert Hauser, Stuart Isaacson, Rajesh Pahwa, Daniel Truong, Eric Pappert, Peter Gardzinski, Bruce Dzyngel, Albert Agro, Alberto Espay (Tampa, FL, USA)
- 78 Efficacy of IPX066, extended-release levodopa-carbidopa in patients with advanced Parkinson's disease: Responder analyses

Suneel Gupta, Sarita Khanna, Nathan Rustay, Robert Rubens, Sherron Kell (Hayward, CA, USA)

79 Protective effects of Myristicin against neurodegeneration in a 6-hydroxydopamine induced model of Parkinson's disease in rats

Ali Moradganjeh (Tehran, Iran)

 Study design of an efficacy and safety phase 3, randomized, double-blind, placebo-controlled trial of APL-130277 in the treatment of OFF episodes (CTH-300)
 C. Warren Olanow, Eric Pappert, Peter Gardzinski, Bruce Dzyngel, Albert Agro (Rye,

NY, USA)

- 81 Improvement in motor and non-motor Parkinson's disease symptoms in patients changed from sinemet ir to rytary after deep brain stimulator placement; a case series Drew Falconer, Mahesh Shenai, Sean Rogers (Alexandria, VA, USA)
- 82 Withdrawn by author
- 83 'Advanced' Parkinson's disease characteristics in clinical practice: Results from the observe-PD study, a crosssectional observational study of 2,615 patients Alfonso Fasano, Leonardo Lopiano, Bulent Elibol, Irina Smolentseva, Klaus Seppi, Annamaria Takats, Koray Onuk, Juan Parra Riaza, Lars Bergmann, Ashley Yegin, Kavita Sail, Zvezdan Pirtosek (Toronto, ON, Canada)
- 84 Improvement in motor and non-motor symptoms in lewy body and Parkinson's dementia patients on rytary as compared to sinemet: A case series Drew Falconer, Mahesh Shenai, Sean Rogers (Alexandria, VA, USA)
- 85 Improvement in motor and non-motor Parkinson's disease symptoms with use of rytary (carbidopa/levodopa) in dopamine-naïve patients; a case series Drew Falconer, Mahesh Shenai, Sean Rogers (Alexandria, VA, USA)
- 86 Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: Results from the Phase 3 study dose titration phase Stuart Isaacson, Alberto Espay, Rajesh Pahwa, Daniel Truong, Eric Pappert, Peter Gardzinski, Bruce Dzyngel, Albert Agro, Robert Hauser (Boca Raton, FL, USA)

- 87 Virtual assistant for rehabilitation exercises of people with Parkinson's disease Pedro Chana-Cuevas, Alvaro Fernandez-Lopez, Elena Herrera-Gomez, Fiorella Barbagelata, Lissette Cabrera (Santiago, Chile)
- 88 Impulse Control Disorder on Parkinson's disease. A new approach from art?

Victoria Aldinio, María Bres Bullrich, Pilar Sánchez de Paz, Gustavo Andres Da Prat de Magalhaes, Galeno Rojas, Virginia Parisi, Gabriel Persi, Emilia Gatto (Buenos Aires, Argentina)

- 89 Retrospective claims database analysis assessing Parkinson's disease treatment patterns in the United States Alexander Niyazov, Francis Vekeman, Amy Guo, David Squillacote, Eric Wu, Susan Criswell (Ardsley, NY, USA)
- 90 Postural balance and elderly quality of life with Parkinson's disease treated with functional training, stationary bike and exergame: Pilot study of a randomized clinical trial Karen Trippo, Daniel Ferraz, Keith Farinha, Ramon Kruschewsky, Jamary Oliveira-Filho (Salvador-Bahia, Brazil)
- 91 Association between deficiencies in implicit learning and dual-task gait performance and balance control in patients with Parkinson's disease Maria Elisa Piemonte, Maria Elisa Piemonte, Matheus D'Alencar, Bruno Monte, Andre Helene, Jefferson Galves (Sao Paulo, Brazil)
- 92 Update to interim results of a long-term open-label safety study of ADS-5102 (amantadine HCI) extended-release capsules for treatment of levodopa-induced dyskinesia (LID) (EASE LID 2 Study) Robert Hauser, Rajesh Pahwa, Caroline Tanner, Wolfgang Oertel, Reed Johnson, Larissa Felt, Mary Stempien (Tampa, FL, USA)

Parkinsonism, MSA, PSP (Secondary and Parkinsonism-Plus)

- 93 Withdrawn by author
- 94 PanMSA consortium database Martin Cesarini, Jose Luis Etcheverry, Ana Sanguinetti, Emanuel Mosto, Irene Litvan, Emilia Gatto (La Plata, Argentina)
- 95 Powassan virus post-encephalitic parkinsonism Shivam Mittal, Anhar Hassan, Joyce Sanchez, Carrie Robertson (Rochester, MN, USA)
- 96 Dementia and severe parkinsonism following Wernicke's encephalopathy - a case report Giorgio Fabiani, Camila Richter, Silvia Scremin (Curitiba, Brazil)

Parkinson's Disease: Cognition

- 97 Predictors of change in the diagnosis of mild cognitive impairment subtypes after attending a cognitive rehabilitation program in Parkinson's disease María Díez-Cirarda, Natalia Ojeda, Javier Peña, Olaia Lucas-Jiménez, María Ángeles Gómez-Beldarrain, Juan Carlos Gómez-Esteban, Naroa Ibarretxe-Bilbao (Bilbao, Spain)
- 98 Cognitive and brain resting-state profile in alphasynucleinopathies Olaia Lucas-Jiménez, Naroa Ibarretxe-Bilbao, Iñigo Gabilondo, Natalia Ojeda, Javier Peña, Alberto Cabrera-Zubizarreta, Rocío Del Pino, María Díez-Cirarda, Juan Carlos Gómez-Esteban (Bilbao, Spain)

99 Does hypertension moderate cognition in Parkinson's disease?

Laura Segala, Katalina McInerney, Joshua Rooks, Sharlet Anderson, Ni Sun-Suslow, Christina Bermudez, Corneliu Luca, Henry Moore, Carlos Singer, Bonnie Levin (Miami, FL, USA)

- 100 Classification of neurocognitive impairment in Spanish speaking Parkinson's disease patients Sharlet Anderson, Christina Bermudez, Ni Sun-Suslow, Laura Segala, Corneliu Luca, Henry Moore, Jonathan Jagid, Gustavo Rey, Bonnie Levin (Chicago, IL, USA)
- 101 The effect of anxiety on cognition in Parkinson's disease Sharlet Anderson, Glenn Stebbins, Bryan Bernard, Alice Witczak-Negron, Jennifer Goldman (Chicago, IL, USA)
- 102 Multicenter study of case series of Parkinson's disease in Central America (Central America movement disorders working group) Fernando Gracia, Ernesto Cornejo-Valse, Ricardo Lopez-Contreras, Daniel Pereira Contreras, Heike Hesse, Walter Diaz, Amilkar Zelaya, Alejandra Medina, Alejandra Molina, Michelle Ortiz, Blas Armién (Panama, Panama)
- 103 The role of social support on cognitive functioning after deep brain stimulation in Parkinson's disease Ni Sun-Suslow, Katalina McInerney, Christina Bermudez, Sharlet Anderson, Laura Segala, Quinn McKinnon, Corneliu Luca, Jonathan Jagid, Henry Moore, Carlos Singer, Bonnie Levin (Coral Gables, FL, USA)
- 104 Which items on the Montreal Cognitive Assessment (MoCA) in Parkinson's disease predict progression from mild cognitive impairment (MCI) to dementia? Melissa Mackenzie, Kristen Sundvick, Jiayue Cai, Daryl Wile, Martin McKeown, Silke Appel-Cresswell (Vancouver, BC, Canada)
- 105 Neuropsychological performances and striatal DAT availability in Brazilian Parkinson's disease subjects: Preliminary findings Luis Tieppo Fornari, Sabrina Cardoso, Camila Carpenedo, Arlete Hilbig, Carlos Roberto Rieder (Porto Alegre, Brazil)
- 106 Predictors of cognitive decline in Parkinson's disease (PD) patients Nino Khizanishvili, Maia Beridze, Nana Kvirkvelia, Maka Khaburzania, Tinatin Kherkheulidze, Tamar Kherkheulidze and Ivane Avazashvili (Tbilisi, Georgia)
- 107 Does exposure to toxins influence cognition in Parkinson's disease?

Katalina McInerney, Christina Bermudez, Laura Segala, Ni Sun-Suslow, Joshua Rooks, Quinn McKinnon, Corneliu Luca, Carlos Singer, Jonathan Jagid, Sharlet Anderson, Bonnie Levin (Miami, FL, USA)

 Cognitive profile of patients with PD: Compared with healthy controls
 Maira Olchik, Annelise Ayres, Sabrina Cardoso, Larissa Freire, Artur Schumacher Schuh, Carlos Roberto Rieder (Porto Alegre, Brazil)

Parkinson's Disease: Genetics

109 LRRK2 analysis in the largest Latin American PD cohort: The LARGE-PD consortium

Mario Cornejo-Olivas, Luis Torres, Mario Velit-Salazar, Miguel Inca-Martinez, Pilar Mazzetti Soler, Carlos Cosentino, Federico Micheli, Claudia Perandones, Elena Dieguez, Victor Raggio, Vitor Tumas, Vanderci Borges, Henrique Ferraz, Carlos Roberto Rieder, Artur Schumacher Schuh, Carlos Velez-Pardo, Marlene Jimenez-Del-Rio, Francisco Lopera, Jorge Chang Castello, Brennie Anreé-Munoz, Ignacio Fernandez Mata, Sarah Waldherr, Dora Yearout, Cyrus Zabetian (Lima, Peru)

- 110 LRRK2-exon 31 mutations in Parkinson's disease patients from Ecuador Jorge Chang Castello, Brennie Andreé Muñoz, Ramiro Burgos, Cyrus Zabetian, Ignacio Mata (Guayaquil, Ecuador)
- 111 Hereditary atypical parkinsonism with novel mutation of the VPS35 and FBXO7 genes Katerina Mensikova, Tereza Bartonikova, Lenka Mikulicová, Radek Vodicka, Radek Vrtel, Marek Godava, Iva Dolinova, Miroslav Vastik, Michaela Kaiserova, Pavel Otruba, Petr Kanovsky (Olomouc, Czech Republic)
- 112 LRRK2, MAPT and HTRA2 mutations in the pedigree of familial neurodegenerative parkinsonism with cognitive deterioration spanning five generations in a genetically isolated population of south-eastern Moravia, Czech Republic Petr Kanovsky, Tereza Bartonikova, Radek Vodicka, Katerina Mensikova, Radek

Vrtel, Marek Godava, Pavel Otruba, Michaela Kaiserova, Miroslav Vastik, Lenka Mikulicová (Olomouc, Czech Republic)

- 113 Occupational pesticide exposure and penetrance of LRRK2 Parkinson's disease (PD) Caroline Tanner, Connie Marras, Karen Marder, Susan Bressman, Roy Alcalay, Rachel Saunders-Pullman, Cheryl Chen Meng, Samuel Goldman, Monica Korell, Marta San Luciano, Eduardo Tolosa, Birgitt Schuele, J William Langston, Alexis Brice, George Mellick, Joaquim Ferreira, Meriem Tazir, Christine Klein, Daniela Berg, Anthony Lang (San Francisco, CA, USA)
- 114 Lewy Body and Tau pathology in a patient with parkinsonism, cognitive decline, rapid progression and the GBA1 T269M variant Hannah Walters, Rachel Saunders-Pullman, John Crary, Deborah Raymond, Susan Bressman (New York, NY, USA)

Parkinson's Disease: Neuroimaging and Neurophysiology

- 115 Amyloid-ß deposition effects microglial activation in Parkinson's disease Christine Ghadery, Yuko Koshimori, Jinhee Kim, Sarah Coakeley, Madeleine Harris, Leigh Christopher, Pablo Rusjan, Anthony Lang, Sylvain Houle, Antonio Strafella (Toronto, ON, Canada)
- 116 The utility of dopamine transporter imaging in clinically uncertain parkinsonian syndrome: Experience from general neurology practice Juebin Huang, Syed Hussain, Vani Vijayakumar, Saumya Goel, Alexander Auchus (Jackson, MS, USA)
- 117 [18F]-AV-1451 Binding to neuromelanin in the substantia nigra in PD and PSP Sarah Coakeley, Sang Soo Cho, Yuko Koshimori, Pablo Rusjan, Anthony Lang, Lorraine Kalia, Elizabeth Slow, Sylvain Houle, Antonio Strafella (Toronto, ON, Canada)
- 118 The patient's perspective: the effect of levodopa on Parkinson's disease symptoms Heidemarie Zach, Michiel Dirkx, Jacobus Pasman, Bastiaan Bloem, Rick Helmich (Vienna, Austria)
- 119 Cognitive stress reduces the effect of levodopa on Parkinson's disease resting tremor Heidemarie Zach, Michiel Dirkx, Jacobus Pasman, Bastiaan Bloem, Rick Helmich (Vienna, Austria)



- 120 Transcranial sonography in real clinical practice: Differential diagnosis between idiopathic Parkinson's disease, atypical parkinsonism andeEssential tremor Talyta Grippe, Pedro Renato Brandão, Danilo Pereira, Flavio Pereira, Marcelo Lobo, Iruena Kessler, Nasser Allam (Brasília, Brazil)
- 121 Hemiparkinsonism after cryptococcal meningoencephalitis in an immunocompetent man Giorgio Fabiani, Raul Martins Filho, Helio Teive (Curitiba, Brazil)

Parkinson's Disease: Non-Motor Symptoms

- 122 Low and high apathy symptoms are associated with distinct brain alterations in Parkinson's disease: A multimodal imaging study Naroa Ibarretxe-Bilbao, Olaia Lucas-Jiménez, Javier Peña, Alberto Cabrera-Zubizarreta, María Díez-Cirarda, Juan Carlos Gómez-Esteban, María Ángeles Gómez-Beldarrain, Natalia Ojeda (Bilbao, Spain)
- 123 Autonomic dysfunction is a key determinant of fatigue in Parkinson's disease Kelvin Chou, Sid Gilman, Nicolaas Bohnen (Ann Arbor, MI, USA)
- 124 Premotor sleep disorders and its impact on the severity in NMSS scale during the course of Parkinson's disease Sara Isais Millan, Ned Davila Avila, Amin Cervantes, Mayela Rodriguez Violante, Karla Salinas, Lidia Mendoza Vega (Mexico City, Mexico)
- 125 Constipation before and after diagnosis of Parkinson's disease Karla Salinas, Sara Isais Millan, Ned Davila Avila, Lidia Mendoza Vega, Mayela Rodriguez Violante, Amin Cervantes (Mexico City, Mexico)
- 126 Relationship between subjective and objective measures of sleepiness in Parkinson's disease Adeel Memon, Raima Memon, Allen Joop, Jennifer Pilkington, Kimberly Wood, Amy Amara (Birmingham, AL, USA)
- 127 Non-motor symptoms in Parkinson's disease patients in El Salvador, Central America Susana Peña Martinez, Alex Medina (Santa Tecla, El Salvador)
- 128 Ease of olfactory assessment in the developing world Alex Medina, Rina Medina, Pedro Gomez, Susana Peña Martinez, Claudia Avila (Tegucigalpa, Honduras)
- 129 Withdrawn by author
- 130 Association between freezing of gait and symptoms of anxiety and depression in people with Parkinson's disease Milla Pimenta, Taísa Nogueira, Dandara Moreira, Carolina Lima, Elen Pinto, Guilherme Valenca, Lorena Almeida (Salvador, Brazil)
- 131 Impact of autonomic neuropathy in surgically treated-Parkinson's disease Michela Rosso, Aristide Merola, Tamour Khan Tareen, Alberto Romagnolo, Maurizio Zibetti, Simona Maule, Leonardo Lopiano, Alberto Espay (Cincinnati, OH, USA)
- 132 Comparison of actigraphy with polysomnographic studies in patients with Parkinson's disease Raima Memon, Adeel Memon, Allen Joop, Jennifer Pilkington, Kimberly Wood, Amy Amara (Birmingham, AL, USA)

Parkinson's Disease: Pathophysiology

- 133 Fluvoxamine maleate normalizes striatal neuronal inflammatory cytokine activity in a parkinsonian rat model associated with depression Ernest Dalle, Willie Daniels, Musa Mabandla (Pietermaritzburg, South Africa)
- Effects of siRNA targeting PGC-1a gene on MPP+-induced SH-SY5Y Cell
 Ye Qin-Yong, Chun Chen, Erwang Si, Juhua Wang (Fuzhou, Peoples Republic of China)
- 135 Withdrawn by author
- 136 Nurr1 based research on pathogenesis and therapy for Parkinson's disease Weidong Le (Dalian, Peoples Republic of China)
- 137 Physical mobility predictors and the bone health in Parkinson's disease Luciano Alves Leandro, Carolina Moreira (Curitiba, Brazil)


Parkinson's Disease: Psychiatric Manifestations

- 138 Impulsive Control Disorder in Parkinson's disease and its relation to other behaviour symptoms Maria Villa, Alejandro Bottini Bonfanti, Daniela Romero, Noelia Flores, Gabriela Orzuza, Marcos Burgos (Salta, Argentina)
- 139 Impulse control disorders in Parkinson's disease: Prevalence and clinical features in the Rush University Movement Disorders Clinic Michael Rossi, Glenn Stebbins, Brandon Barton (Chicago, IL, USA)

Phenomenology and Clinical Assessment of Movement Disorders

- 140 Diagnostic accuracy of common bedside ataxia examination tests Rebecca Thompson, Peter Woolman, Danish Bhatti, Amy Hellman, John Bertoni, Diego Torres-Russotto (Omaha, NE, USA)
- 141 Movement disorders cases from a small Caribbean island Shruthi Rethi (Calgary, AB, Canada)
- 142 Post-stroke movement disorders in Santa Clara, Cuba Miriam Batule Dominguez (Santa Clara, Cuba)
- 143 Objective assessment of bradykinesia and dyskinesia in advanced Parkinson's disease Ammar Rasul, Ashar Farooqi, Joseph Martinez, Jason Margolesky, Corneliu Luca (Miami, FL, USA)
- Predicting multiple falls in people with Parkinson's disease:
 A statistical approach
 Lorena Almeida, Natalie Allen, Colleen Canning, Catherine Sherrington,
 Guilherme Valenca, Jamary Oliveira-Filho, Serene Paul (Salvador, Brazil)
- 145 Withdrawn by author
- 146 How to assess functional capacity upper limbs in patients with Parkinson's disease and atypical parkinsonism? Tamine Capato, Rubia Magalhaes, Thamires Silva, Lygia Nogueira, Cynthia Dionizio, Egberto Barbosa (Sao Paulo, Brazil)

FURTHER, **TOGETHER**



At Medtronic, we're changing what it means to live with chronic disease. We're creating innovative therapies that help patients get back to enjoying some of the things in life they thought they had lost forever. Seeing our work improve lives is a powerful motivator. The more we do, the more we're driven to push the boundaries of medical technology.

To learn more about Medtronic, visit MedtronicDBS.com.



Medtronic



Surgical Therapy: Other Movement Disorders Technology

- 147 Successful unilateral GPi and VIM Deep Brain Stimulation in a case of Dystonia Myoclonus Verónica Montilla-Uzcátegui, Carolina Ramírez Gómez, Carol Aguilar Alvarado, Gonzalo Castro, Fabián Piedimonte, Federico Micheli (Buenos Aires, Argentina)
- 148 Effect of thalamic deep brain stimulation on postural balance in subjects with essential tremor Ashar Farooqi, Ammar Rasul, Joseph Martinez, Victor Velez-Aldahondo, Jonathan Jagid, Corneliu Luca (Miami, FL, USA)

Surgical Therapy: Parkinson's Disease

- 149 Deep brain stimulation for Parkinson's disease: Short-term outcomes, referral patterns and health disparities Daniel Garbin Di Luca, Victor Velez-Aldahondo, Walter Jermakowicz, Laura Segala, Henry Moore, Carlos Singer, Bonnie Levin, Jonathan Jagid, Corneliu Luca (Miami Beach, FL, USA)
- 150 Intraoperative recording from the red nucleus during deep brain stimulation surgery Tamour Khan Tareen, George Mandybur, Kevin Biddell, Hilary Perez, Alberto Espay, Andrew Duker, Aristide Merola (Cincinnati, OH, USA)

Late-Breaking Abstracts

LBA 01 Comparative time course changes between Parkinson's disease and age-matched elders during power resistance training

Joseph Signorile, Kirk Roberson, Melanie Potiaumpai, Savannah Wooten (Miami, FL, USA)

- LBA 02 Assessing changes in physical function, cognitive function, and quality of life in individuals with Parkinson's disease Bryan Riemann, Kaitlyn Stanfield, Jessica Santaniello, Michael Cohen (Savannah, GA, USA)
- LBA 03 The efficacy of an intensive piano training program on information processing speed in adults with Parkinson's disease Jennifer Bugos, Teresa Lesiuk (Miami, FL, USA)

LBA 04 Discordance between neurophysiologic and radiographic subthalamic nucleus during microelectrode recording in patients with Parkinson's disease Ryan Kochanski, Sander Bus, Gian Pal, Leo Verhagen Metman, Sepehr Sani (Chicago, IL, USA)

Lundbeck Proudly Supports International Parkinson and Movement Disorder Society

Our mission, to improve the quality of life for people diagnosed with brain disorders, fuels our passion and drives us forward to make a difference... one patient at a time.

To learn more about Lundbeck, visit www.lundbeckus.com.



UBR-C-00055 9/2014

Corporate Therapeutic Symposia

These company-based information sessions will provide attendees with non-CME educational opportunities to learn the latest in therapeutics.

Saturday, February 25, 2017

Sunday, February 26, 2017

	Acadia Pharmaceuticals		AbbVie
	12:15-13:15		12:15-13:15
Location:	Brickell Room	Location:	Chopin Ballroom
	Treating Hallucinations and Delusions Associated		Reevaluating Our Approach to Parkinson's
	With Parkinson's Disease Psychosis		Disease and Disease Progression
Speakers:	Alberto Espay	Speakers:	Hubert Fernandez
	Cincinnati, OH, USA		Cleveland, OH, USA
	Tanya Simuni		Alberto Espay
	Chicago, IL, USA		Cincinnati, OH, USA
	Sunovion		
	12:15-13:15		
Location:	Chopin Ballroom		
	A Practical Approach to OFF Episodes in		
	Parkinson's Disease		
Speakers:	Charles Adler		
	Scottsdale, AZ, USA		
	Stewart Factor		
	Atlanta, GA, USA		
	Anthony Lang		
	Toronto, ON, Canada		





Acknowledgements

The 1st Pan American Parkinson's Disease and Movement Disorders Congress Oversight Committee wishes to acknowledge and thank the following companies for their support:

Platinum Level







Gold Level



Medtronic





Silver Level



Bronze Level



Education Grant Supporters:

MDS acknowledges the supporters of the following PAS Congress activities through educational grants:

Themed Plenary Session 1101: Parkinson's Disease Across the Americas, supported by Roche

Parallel Session 1204: Dopaminergic and Cholinergic Imaging in Parkinson's Disease, supported by GE Healthcare

Parallel Session 2205: Parkinson's Disease Across the PAS: Cross- Cultural Influences on its Neuropsychiatric Issues, supported ACADIA Pharmaceuticals

Above companies are confirmed as of December 21, 2016

Notes

Corporate Therapeutic Symposium

Hosted by ACADIA Pharmaceuticals

Saturday, February 25, 2017 12:15 - 13:15

Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis



Alberto J. Espay, MD, MSc, FAAN Associate Professor of Neurology Director and Endowed Chair

James J. and Joan A. Gardner Center for Parkinson's Disease and Movement Disorders University of Cincinnati Academic Health Center



Tanya Simuni, MD

Arthur C. Nielsen, Jr., Professor of Neurology Director, Parkinson's Disease and Movement Disorders Center Northwestern University Feinberg School of Medicine

LOCATION

InterContinental Hotel Miami 100 Chopin Plaza, Miami, FL 33131

Brickell Room

LEARNING OBJECTIVES

- Understand the symptoms, diagnosis, and impact of Parkinson's disease psychosis (PDP)
- Explore the proposed mechanism of action of NUPLAZID (pimavanserin)
- Discuss the efficacy, safety, and administration of NUPLAZID for the treatment of hallucinations and delusions associated with PDP

Sponsored by



SEATING IS AVAILABLE ON A FIRST-COME, FIRST-SERVED BASIS; NO PRE-REGISTRATION REQUIRED

Important Safety Information for NUPLAZID (pimavanserin) 17-mg Tablets

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson's disease psychosis.

QT Interval Prolongation: NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics. NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.

Adverse Reactions: The most common adverse reactions ($\geq 2\%$ for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).

Drug Interactions: Strong CYP3A4 inhibitors (eg, ketoconazole) increase NUPLAZID concentrations. Reduce the NUPLAZID dose by one-half. Strong CYP3A4 inducers may reduce NUPLAZID exposure, monitor for reduced efficacy. Increase in NUPLAZID dosage may be needed.

Renal Impairment: No dosage adjustment for NUPLAZID is needed in patients with mild to moderate renal impairment. Use of NUPLAZID is not recommended in patients with severe renal impairment.

Hepatic Impairment: Use of NUPLAZID is not recommended in patients with hepatic impairment. NUPLAZID has not been evaluated in this patient population.

Pregnancy: Use of NUPLAZID in pregnant women has not been evaluated and should therefore be used in pregnancy only if the potential benefit justifies the potential risk to the mother and fetus.

Pediatric Use: Safety and efficacy have not been established in pediatric patients.

Dosage and Administration

Recommended dose: 34 mg per day, taken orally as two 17-mg tablets once daily, without titration.

Indication

NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.



For full Prescribing Information, please visit www.NUPLAZIDhcp.com. ©2016 ACADIA Pharmaceuticals Inc. All rights reserved. NU-0429 12/16



Symposium: February 25, 2017 12:15 to 1:15 PM

Faculty: Chuck Adler, MD, PhD, Scottsdale, AZ (Chair) Stewart Factor, DO, Atlanta, GA Anthony Lang, OC, MD, Toronto, ON, Canada

Title: A Practical Approach to OFF Episodes in Parkinson's Disease

Abstract:

The reemergence of Parkinson's disease (PD) symptoms (motor and non-motor) in treated patients is referred to as an OFF episode. OFF episodes are thought to occur when brain dopamine levels fall below a critical threshold to sustain relatively normal function, known as ON time. It is important to note that patients may still experience OFF periods despite optimized medical treatment. However, to date, there has been little consensus regarding the definition of OFF or how to measure it. Physicians and patients need to communicate more effectively about OFF episodes. OFF episodes negatively impact the quality of life in patients with PD and increase the burden of illness. This symposium will focus on the identification and treatment of OFF episodes and current unmet needs.

Phenomenology, clinical significance and risk factors for the development of OFF episodes in PD—**Anthony Lang, OC, MD**

Current and novel approaches to the treatment of OFF episodes in PD-Stewart Factor, DO

Panel Discussion—Chuck Adler, MD, PhD, Stewart Factor, DO, Anthony Lang, OC, MD

This non-CME program is sponsored by Sunovion CNS Development Canada



SUNOVION and 35 are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd ©2016 Sunovion Pharmaceuticals Inc. All rights reserved. 84 Waterford Drive, Marlborough, MA 01752

Advance. Improve. Educate. Collaborate.



Become a Member of MDS

Meet & Collaborate with over 6,000 colleagues across the globe and become a part of a Medical and Educational community dedicated to disseminating knowledge and promoting research to advance the field of Movement Disorders



Peer Reviewed Journals: *Movement Disorders* and *Movement Disorders – Clinical Practice*

Quarterly Newsletter: Moving Along

Reduced Course Registration Rates

Online Resources: CME Activities; Streaming Content; Training Videos; And a Video Library with over 1,800 searchable videos

NON-MEMBER OPPORTUNITIES

Free One-Year Trial Membership Open to Eligible PAS Congress Delegates

ASSOCIATE MEMBERSHIP

Non-members attending the PAS Congress have the opportunity to receive membership with MDS absolutely free for a year. Eligible participants will be invited by e-mail to apply for free Associate Membership. Interested individuals are encouraged to apply online within 30 days of contact.

Learn more at www.movementdisorders.org/associate-membership.htm or contact the International Secretariat:



MDS International Secretariat 555 East Wells Street, Suite 1100 Milwaukee, WI 53202 USA Tel: +1 414-276-2145 Fax: +1 414-276-3349 E-mail: info@movementdisorders.org

